US/UK/Canada

Share

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Pick a time period -
Tags ( Active)

Gambro BCT's blood collection system approved by Japanese Red Cross

Gambro BCT's blood collection system approved by Japanese Red Cross Stockholm, Sweden, December 9, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that its subsidiary Gambro BCT has received approval from the Japanese Red Cross for its automated blood collection system for collection of leukoreduced platelets and plasma. The approval of the Trima Accel System represents a major milestone for Gambro BCT on the Japanese market. During the autumn of 2003, marketing trials were conducted in four blood

Gambro won tax ruling

Gambro won tax ruling Stockholm, Sweden, November 27, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that the Lower Tax Court (Länsrätten) has confirmed the advance ruling by the Supreme Administrative Court regarding the fiscal acquisition value of previously divested ABB shares. The ruling means that Gambro has been given access to approximately MSEK 2,182 of carry-forward losses with a tax effect of MSEK 611. Together with an earlier ruling this corresponds to a tax saving of MSEK 894, which will be

Nomination of Board Members for the 2004 Annual General Meeting

Nomination of Board Members for the 2004 Annual General Meeting Stockholm, Sweden, November 11, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that in accordance with the decision made by Gambro's Annual General Meeting on April 10, 2003, it is hereby announced that the following persons, representing the largest shareholders in Gambro AB, together with the Chairman of the Board, Claes Dahlbäck, who represents Investor AB, will make a proposal for the composition of the Board of Directors, to be

Jon Risfelt new President of Gambro Renal Products

Jon Risfelt new President of Gambro Renal Products Stockholm, Sweden, October 30, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Jon Risfelt has been elected acting President of Gambro Renal Products. He is succeeding Alain Granger, who has decided to move to a position as senior advisor to the company. Jon Risfelt has a broad experience from management positions in international companies. Recently he was President and CEO of Vodafone Sweden. He joins Gambro as of November 3, 2003. Jon Risfelt has

Nine month report January-September 2003

Nine month report January-September 2003 · Revenues up 8% currency adjusted · Operating earnings, EBITDA, up 11% currency adjusted · Earnings before tax, EBT, up 69% · Earnings per share increased to SEK 1.58 (0.66) · Strong operating cash flow at MSEK 1,312 (932) · Net debt reduced by SEK 1.8 billion since January 1, 2003 FOR FURTHER INFORMATION PLEASE CONTACT: Lars Granlöf, SVP, CFO, tel. +46-8-613 65 00, +46 70 513 65 48 Bengt Modéer, SVP, Corporate Communications, tel. +46 8 613 65 00, +46 70 513 65 33 Pia Irell, Director, Investor Relations, tel. +46 8 613 65 91, +46 70 513 65 91 Kevin

Gambro chosen for Dow Jones Sustainability World Index

Gambro chosen for Dow Jones Sustainability World Index Stockholm, Sweden, October 22, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has been chosen for the Dow Jones Sustainability World Index family based on the company's ability to balance environmental excellence, social responsibility and financial success. Launched in 1999, the Dow Jones Sustainability Indexes (DJSI) are the world's first global indexes tracking the performance of the leading sustainability-driven companies worldwide. The

Navigant Biotechnologies Awarded USD 2 M Department of Defense Research Funding

Navigant Biotechnologies Awarded $2M Department of Defense Research Funding Funding will enable Navigant to develop military applications for its emerging riboflavin-based pathogen reduction technology, improving the safety of blood supply for U.S. Troops. Lakewood, CO - October 21, 2003 - Navigant Biotechnologies, Inc. today announced that it was awarded $2 million in funding from the U.S. Department of Defense to develop and test military applications for the company's emerging Mirasol(TM) Pathogen Reduction Technology (PRT). Mirasol PRT is a proprietary technology that uses riboflavin

Gambro BCT's platelet technology cleared by the US Food and Drug Administration for seven day storage (Local US press re

Gambro BCT's platelet technology cleared by the US Food and Drug Administration for seven day storage (Local US press release) Denver, CO October 20, 2003 - Gambro BCT, Inc., a wholly owned subsidiary of Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that platelets collected with its automated blood collection system, Trima®, and the blood components collection and separation system, Spectra(TM), can be stored safely and effectively for up to seven days. This is a significant increase over the previously

US FDA clears Gambro BCT's software for interface with blood center information systems (Local US press release)

US FDA clears Gambro BCT's software for interface with blood center information systems (Local US press release) Denver, CO, October 15, 2003 - Gambro BCT, Inc., a wholly owned subsidiary of Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has received US Food and Drug Administration market clearance for the two-way software interface between the Vista(TM) Information System and Wyndgate Technologies®' SafeTrace® blood center software, to share critical donor, blood collection and blood center

Navigant Biotechnologies launches website

Navigant Biotechnologies launches website Site mirrors company's technology: simple and effective Stockholm, Sweden, August 7, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Navigant Biotechnologies, Inc., a Denver, US based and wholly owned subsidiary of Gambro, Inc., has launched its new website: www.navigantbiotech.com. The new site includes links to a comprehensive group of scientific abstracts describing the company's breakthrough Mirasol(TM) Pathogen Reduction Technology (PRT). Mirasol PRT is

Six month report January-June 2003

Six month report January-June 2003 · Revenue growth in line with company's outlook, up 8% currency adjusted · Operating earnings, EBITDA, up 11% currency adjusted · Earnings before tax, EBT, up 76% · Earnings per share increased to SEK 0.98 (0.39) · Strong operating cash flow at MSEK 582 (480) MSEK Q2 Currency January-June Currency 2003 2002 Nomi adjusted 2003 2002 Nomi adjusted nal nal Revenues 6,527 7,053 -7% +7% 13,036 13,962 -7% +8% EBITDA 1,100 1,126 -2% +10% 2,206 2,232 -1% +11% EBITDA 16.9% 16.0% 16.9% 16.0% margin EBT 493 238 +107% 856 486 +76% EBT margin 7.6% 3.4% 6.6% 3.5%

Gambro receives US 510(k) approval for new dialyzer for treatment of renal failure

Gambro receives US 510(k) approval for new dialyzer for treatment of renal failure Stockholm, Sweden, July 8, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Gambro Renal Products in the United States has received FDA clearance of the 510(k) Notification for the Polyflux® LR Hemodialyzer. This is the newest member of its Polyflux hemodialyzer product line, used for the treatment of chronic and acute renal failure. The Polyflux LR may be reprocessed for reuse on the same patient. "Responding to our

Gambro BCT and MAK-SYSTEM collaborate to help blood centers optimize automated blood collection

Gambro BCT and MAK-SYSTEM collaborate to help blood centers optimize automated blood collection Denver, CO and Paris, France, July 1, 2003- Gambro BCT, Inc., a wholly owned subsidiary of Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, and MAK- SYSTEM International Group, a world leader in developing software for managing blood banks and blood transfusion activities, today announced an alliance to integrate MAK-SYSTEM's PROGESA® software suite with the Gambro BCT Vista(TM) Information System in order to share critical donor,

Three month report January-March 2003

Three month report January-March 2003 · Revenue growth in line with company's outlook, up 8% currency adjusted · Operating earnings, EBITDA, up 12% currency adjusted · Earnings before tax, EBT, up 46% · Strong operating cash flow at MSEK 281 (144) · Earnings per share increased to SEK 0.40 (0.26) Stockholm, April 25, 2003 Sören Mellstig President and CEO FOR FURTHER INFORMATION PLEASE CONTACT: Lars Granlöf, SVP, CFO, tel. +46-8-613 65 00, +46 70 513 65 48 Bengt Modéer, SVP, Corporate Communications, tel. +46 8 613 65 00, +46 70 513 65 33 Pia Irell, Director, Investor Relations, tel. +46 8

Verdict received in US dispute involving Gambro

Verdict received in US dispute involving Gambro Stockholm, Sweden, April 23, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that a jury verdict was received in a lawsuit that had been pending in a United States court in Florida for approximately six years. As outlined in the Gambro Annual Report 2002 (Note 31), the lawsuit, Ginsburg et al. vs. Gambro et al., relates to a 1995 tender offer to all public stockholders in REN Corporation US (REN) pursuant to which Gambro, Inc. acquired all of the remaining

Report from Gambro's Annual General Meeting, April 10, 2003

Report from Gambro's Annual General Meeting, April 10, 2003 Stockholm, Sweden, April 11, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, reports the following decisions taken at the Annual General Meeting. Board of Directors Claes Dahlbäck, Sandra Austin Crayton, Wilbur H Gantz, Peter H Grassmann, Juha P Kokko, Sören Mellstig and Håkan Mogren were reelected members of the Board. Lena Torell was elected new member of the Board. At the statutory Board meeting following the Annual General Meeting, Claes Dahlbäck was

Gambro continues capacity expansion for dialyzers

Gambro continues capacity expansion for dialyzers Stockholm, Sweden, March 24, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has decided to substantially expand its production capacity of synthetic membrane dialyzers. The investment will add new production lines in Hechingen, Germany. The new plant will enable Gambro to increase its production capacity by five million units annually. The site in Hechingen manufactures dialyzers to both external customers and to Gambro Healthcare clinics in the

Gambro publishes Annual Report on the Internet

Gambro publishes Annual Report on the Internet Stockholm, Sweden, March 19, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it is publishing the Annual Report for 2002 today. The report is available on Gambro's website on the Internet, www.gambro.com. The printed version of the Annual Report will be available and distributed the week commencing March 24, 2003 to the shareholders and other stakeholders who have notified Gambro that they continuously would like to receive financial information from

Lena Torell proposed for the Gambro Board

Lena Torell proposed for the Gambro Board Stockholm, Sweden, March 13, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that shareholders representing more than 40 percent of the votes in the Company have indicated that they will propose that Professor Lena Torell, President of the Royal Swedish Academy of Engineering Sciences (IVA) be elected a new member of the Gambro Board of Directors at the Annual General Meeting on April 10, 2003. Since 2001 Lena Torell is President of IVA, an academy with the

The Board of Directors of Gambro resolves on a Stock Incentive Program for the Group

The Board of Directors of Gambro resolves on a Stock Incentive Program for the Group Background The Board of Directors of Gambro AB ("Gambro") has resolved to introduce a Stock Incentive Program consisting of three parts; a stock option program, similar to the programs introduced in 1999-2002 which are described in the annual report of Gambro, and two new types of programs based on allotment of shares pursuant to an American model (a so-called restricted stock program and a so-called performance share program). The Board of Directors has, with assistance from the Compensation Committee and

Gambro to focus development of dialysis monitors

Gambro to focus development of dialysis monitors Stockholm, Sweden, March 4, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced to focus and strengthen development of monitors within the Renal Products business. Development responsibility and resources for hemodialysis monitors will be focused to existing development units in Medolla, Italy. This involves a shift from Lund, Sweden. Similarily monitor development responsibility and resources for renal intensive care will be transferred to Lund, Sweden from

Theresa Ayers appointed President and CEO of Navigant Biotechnologies Inc., Gambro's subsidiary for Pathogen Reduction T

Theresa Ayers appointed President and CEO of Navigant Biotechnologies, Inc., Gambro's subsidiary for Pathogen Reduction Technology Stockholm, Sweden, February 20, 2003 Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has hired Teresa Ayers, to head Navigant Biotechnologies, Inc. This is the new name for Gambro Pathogen Reduction Technology, Inc., a company established last year by Gambro BCT to commercialize its break-through pathogen reduction technology. Both announcements reflect Navigant

Fourth quarter and year end report 2002

Fourth quarter and year end report 2002 Full year 2002 highlights: · Group revenues increased 9% currency adjusted, good organic growth in all business areas · Operating earnings, EBITDA, up 11% currency adjusted · Strong operating cash flow at MSEK 1,540 (-11) · Earnings per share increased to SEK 1.05 (0.39); SEK 1.78 incl. reversal of tax provisions · Dividend proposal SEK 1.10 (1.10) ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/

There are no items matching the current filter
There are no more items matching the current filter
Back to top